Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ:ELDN) has announced a conference call and webcast scheduled for August 6, 2025, at 4:30 p.m. ET to discuss updated clinical data from their ongoing Phase 1b study of tegoprubart in kidney transplantation.

The presentation will feature data from approximately 30 kidney transplant recipients and will be presented at the World Transplant Congress (WTC) in San Francisco. The study focuses on tegoprubart's potential in preventing rejection in kidney transplant patients.

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025.

To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conference ID is 34575. Registration for the live webcast can be found here and available on the “Events” section of Eledon’s website at www.eledon.com. The webcast will be archived on the website following the completion of the call.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com

Source: Eledon Pharmaceuticals

FAQ

When is Eledon Pharmaceuticals (ELDN) hosting its conference call to discuss tegoprubart kidney transplant data?

Eledon will host the conference call on August 6, 2025, at 4:30 p.m. ET to discuss updated clinical data from their Phase 1b study.

How many patients are included in Eledon's (ELDN) tegoprubart kidney transplant study?

The study includes data from approximately 30 kidney transplant recipients.

What is the purpose of Eledon's (ELDN) tegoprubart Phase 1b study?

The Phase 1b study evaluates tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation.

How can investors access Eledon's (ELDN) conference call on August 6?

Investors can dial 1-800-717-1738 (domestic) or 1-646-307-1865 (international) with conference ID 34575, or access the webcast through Eledon's website at www.eledon.com.